Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · IEX Real-Time Price · USD
70.88
-1.76 (-2.42%)
May 17, 2024, 4:00 PM EDT - Market closed
Nuvalent Employees
Nuvalent had 92 employees on December 31, 2023. The number of employees increased by 30 or 48.39% compared to the previous year.
Employees
92
Change (1Y)
30
Growth (1Y)
48.39%
Revenue / Employee
n/a
Profits / Employee
-$1,581,620
Market Cap
4.57B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 92 | 30 | 48.39% |
Dec 31, 2022 | 62 | 22 | 55.00% |
Dec 31, 2021 | 40 | 13 | 48.15% |
Dec 31, 2020 | 27 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
Merit Medical Systems | 6,950 |
Haemonetics | 3,034 |
Oscar Health | 2,400 |
Inspire Medical Systems | 1,011 |
TransMedics Group | 584 |
CRISPR Therapeutics AG | 407 |
Madrigal Pharmaceuticals | 376 |
NUVL News
- 1 day ago - Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 - PRNewsWire
- 9 days ago - Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results - PRNewsWire
- 5 weeks ago - Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire
- 2 months ago - Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire
- 2 months ago - Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 2 months ago - Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 - PRNewsWire
- 3 months ago - Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors - PRNewsWire
- 3 months ago - Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - PRNewsWire